Here are the 8-K filings from Regulus Therapeutics Inc. (RGLS) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An 8-K covers material events a company has to report between its quarterly reports, so if you follow RGLS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RGLS filings page.
Regulus Therapeutics (NASDAQ:RGLS) announced the completion of its acquisition by Novartis AG through a tender offer and subsequent merger. Novartis acquired RGLS shares for $7.00 in cash per share plus one non-tradeable contingent value right (CVR) worth up to an additional $7.00 per share upon achievement of specified milestones. The tender offer expired on June 24, 2025, with approximately 74.49% of shares validly tendered. Following the tender offer, Merger Sub merged with Regulus on June 25, 2025, making Regulus an indirect wholly-owned subsidiary of Novartis. The deal included provisions for the conversion of stock options, RSUs, and PSUs into cash consideration plus CVRs.